Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

por Awada, A, Hendlisz, A, Gil, T, Bartholomeus, S, Mano, M, de Valeriola, D, Strumberg, D, Brendel, E, Haase, C G, Schwartz, B, Piccart, M
Publicado 2005